(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
0.00% IDR 1 490.00
Live Chart Being Loaded With Signals
PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through four divisions: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution and Logistic...
Stats | |
---|---|
Dagens volum | 24.97M |
Gjennomsnittsvolum | 36.05M |
Markedsverdi | 68 920.87B |
EPS | IDR0 ( 2024-04-28 ) |
Neste inntjeningsdato | ( IDR18.16 ) 2024-08-02 |
Last Dividend | IDR0 ( N/A ) |
Next Dividend | IDR0 ( N/A ) |
P/E | 24.94 |
ATR14 | IDR4.31 (0.29%) |
Volum Korrelasjon
PT Kalbe Farma Tbk. Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
PT Kalbe Farma Tbk. Korrelasjon - Valuta/Råvare
PT Kalbe Farma Tbk. Økonomi
Annual | 2023 |
Omsetning: | IDR30 449.13B |
Bruttogevinst: | IDR11 438.05B (37.56 %) |
EPS: | IDR59.81 |
FY | 2023 |
Omsetning: | IDR30 449.13B |
Bruttogevinst: | IDR11 438.05B (37.56 %) |
EPS: | IDR59.81 |
FY | 2022 |
Omsetning: | IDR28 933.50B |
Bruttogevinst: | IDR11 704.07B (40.45 %) |
EPS: | IDR72.71 |
FY | 2021 |
Omsetning: | IDR26 261.19B |
Bruttogevinst: | IDR11 283.78B (42.97 %) |
EPS: | IDR67.92 |
Financial Reports:
No articles found.
PT Kalbe Farma Tbk.
PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through four divisions: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution and Logistic. It offers generic, branded, and licensed drugs, including Brainact, Cefspan, Mycoral, Cernevit, Cravit, Neuralgin, Broadced, Neurotam, Hemapo, and CPG that are distributed to hospitals, pharmacies, and drug stores. The company also provides over-the-counter drugs; energy drinks, ready-to-drink products, supplements, and other preventive products; and nutritional products for infants, toddlers, children, teenagers, adults, pregnant and lactating women, and elders, as well as for consumers with special medical needs. In addition, it offers contract services, including clinical study management, bioavailability/bioequivalence studies, and contract analysis to pharmaceutical companies; and animal health products, as well as operates Mitrasana Clinics, a health care service. Further, the company provides health screening services; operates as an agent and representative for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as offers advertising services. PT Kalbe Farma Tbk. was incorporated in 1966 and is headquartered in Jakarta, Indonesia.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.